Ranbaxy scouts India for FDA-approved plants; Roche tests Nutley area for groundwater contamination;

@FiercePharma: Sanofi chief's latest growth promise: Q4 will bring it. Story | Follow @FiercePharma

@EricPFierce: FDA approved another new hot flash drug, this one from Pfizer, Ligand. ICYMI last week | Follow @EricPFierce

@CarlyHFierce: ICYMI: Activist investor fumes over Otsuka bid for Astex. More | Follow @CarlyHFierce

> India's Ranbaxy Laboratories is shopping for an FDA-approved manufacturing facility in its home country, aiming to shift production from troubled plants so it can be sure to launch new drugs as planned. Report

> Roche ($RHHBY) is drilling exploratory water wells to determine whether chemical contamination at its site in Nutley, NJ, extends to groundwater off-site. Report

> A South Dakota jury ruled that Johnson & Johnson ($JNJ) should warn consumers of a link between ovarian cancer and the use of talc-based body powder but awarded no damages to the cancer patient who sued. Report

> A Dutch court upheld a patent on Teva Pharmaceutical Industries' ($TEVA) multiple sclerosis drug Copaxone; Mylan ($MYL) had challenged Teva's European IP protection on the drug, which expires in May 2015. Report

> A Tennessee patient treated in the U.S. meningitis outbreak tied to contaminated steroids from a compounding pharmacy has relapsed. Report

Medical Device News

@FierceMedDev: Edwards' stock starts rebounding after FDA expanded approval for Sapien valve. ICYMI Friday | Follow @FierceMedDev

@MarkHFierce: Atossa is issuing a voluntary recall of its breast cancer test to address FDA regulatory concerns. News | Release | Follow @MarkHFierce

@MichaelGFierce: Check out FierceBiotech's new mobile app! Here's some more info | Follow @MichaelGFierce

> FDA: Medtronic, CardioMEMS panel reviews are on despite government shutdown. Story

> Delcath axes one-third of staff after FDA rejection. More

> Boreal Genomics raises $18M to support Dx test and genomic tool expansion. Item

Biotech News

@FierceBiotech: Still trending: What happens to the  in a government shutdown? Story | Follow @FierceBiotech

@JohnCFierce: Pharma companies paid $25K to attend academics' summit on FDA trial rules. Pay to play. Report | Follow @JohnCFierce

@DamianFierce: Analyst: Bet on another boom for big CROs. More from FierceCRO | Follow @DamianFierce

@EmilyMFierce: Chemical in red wine kills cancer cells even after it's metabolized. Story from FierceBiotech Research | Follow @EmilyMFierce

> Novo Nordisk betting $3.7B on a blockbuster oral diabetes drug market. Story

> GlaxoSmithKline's Duchenne MD drug mirrors placebo effect in PhIII. More

> GlycoMimetics, Karyopharm ride the wave of new biotech IPOs. Article

CRO News

> Analyst: Bet on another boom for big CROs. Report

> Covance launches lab management service to cut study costs. Article

> Biocon: Syngene is Asia's fastest-growing CRO. Item

> Boehringer pulls plug on CMO biz, plots 1,100 job cuts. Story

> CRO TranScrip reaches into Hong Kong. News

> AMRI snags drug development deal with U.K. government. More

Biotech IT News

> IBM updates open-source Big Data disease modeling platform. Report

> Low-profile cloud service provider steps into limelight. Item

> Ambitious U.K. genome project looks for industry input. News

> Bioinformatics projects stall as shutdown stops NIH funding. Story

> Bill advances case for nationwide track-and-trace databases. More

> Experts tip bioinformatics collaborations to improve breast cancer care. Article

And Finally... Three scientists won the Nobel Prize in Medicine for cracking the puzzle of how cells transport crucial substances to the right place at the right time. Report (sub. req.)

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.